Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies by Matrana, M.R, Duran, C, Shetty, A, Xiao, L, Atkinson, B.J, Corn, P, Pagliaro, L.C, Millikan, R.E, Charnsangave, C, Jonasch, E, Tannir, N.M

Get full text

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) by Schmidinger, M, Motzer, R.J, Powles, T, Escudier, B, Tannir, N.M, Mainwaring, P.N, Rini, B.I, Hammers, H.J, Donscov, F, Roth, B, Peltola, K, Lee, J.L, Heng, D.Y.C, Aftab, D.T, Hessel, C, Scheffold, C, Schwab, G, Pal, S, Hutson, T.E, Choueiri, T.K

Get full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors by Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

Get full text

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis by Campbell, Matthew T., Bilen, Mehmet A., Shah, Amishi Y., Lemke, Emily, Jonasch, E., Venkatesan, A.M., Altinmakas, E., Duran, C., Msaouel, Pavlos, Tannir, N.M.

Get full text

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis by Liu, X-D, Yao, J, Tripathi, D N, Ding, Z, Xu, Y, Sun, M, Zhang, J, Bai, S, German, P, Hoang, A, Zhou, L, Jonasch, D, Zhang, X, Conti, C J, Efstathiou, E, Tannir, N M, Eissa, N T, Mills, G B, Walker, C L, Jonasch, E

Get full text

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma by Ho, T H, Park, I Y, Zhao, H, Tong, P, Champion, M D, Yan, H, Monzon, F A, Hoang, A, Tamboli, P, Parker, A S, Joseph, R W, Qiao, W, Dykema, K, Tannir, N M, Castle, E P, Nunez-Nateras, R, Teh, B T, Wang, J, Walker, C L, Hung, M-C, Jonasch, E

Get full text

P183 Nivolumab Plus Ipilimumab (NIVO+IPI) vs Sunitinib (SUN) for first-line treatment of advanced Renal Cell Carcinoma (aRCC): Efficacy across number of International Metastatic Re... by Escudier, B., Motzer, R.J., Tannir, N.M., Rini, B.I., Porta, C., Tomita, Y., Fedorov, V., Desilva, H., Jiang, R., Grünwald, V.

Get full text

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials by Amini, B, Beaman, C B, Madewell, J E, Allen, P K, Rhines, L D, Tatsui, C E, Tannir, N M, Li, J, Brown, P D, Ghia, A J

Get full text

2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) by Schmidinger, M., Motzer, R.J., Powles, T., Escudier, B., Tannir, N.M., Mainwaring, P.N., Rini, B.I., Hammers, H.J., Donscov, F., Roth, B., Peltola, K., Lee, J.L., Heng, D.Y.C., Aftab, D.T., Hessel, C., Scheffold, C., Schwab, G., Pal, S., Hutson, T.E., Choueiri, T.K.

Get full text

O2 - Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial by Schmidinger, M., Powles, T., Motzer, R.J., Rolland, F., Gravis, G., Staehler, M., Rink, M., Retz, M., Csoszi, T., Mccaffrey, J.A., De Giorgi, U., Caserta, C., Duran, I., Larkin, J.G., Benzaghou, F., Clary, D., Escudier, B., Choueir, T.K., Tannir, N.M.

Get full text

Cabozantinib versus everolimus in patients with advanced renal cell carcinoma from Europe and the rest of the world: subgroup analysis of the METEOR trial by Schmidinger, M., Powles, T., Motzer, R.J., Rolland, F., Gravis, G., Staehler, M., Rink, M., Retz, M., Csoszi, T., Mccaffrey, J.A., De Giorgi, U., Caserta, C., Duran, I., Larkin, J.G., Benzaghou, F., Clary, D., Escudier, B., Choueir, T.K., Tannir, N.M.

Get full text